NCT06407193

Brief Summary

Sleeve gastrectomy (SG) increases gastrointestinal motility, which influences feelings of fullness and satiety. By understanding the differences in gastric emptying (GE) between patients with sufficient weight loss (Total weight loss \[TWL\] \> 35%) and insufficient weight loss (TWL \< 25%), better insight in the aetiology of weight loss after sleeve gastrectomy may be obtained. GE will be measured with scintigraphy and MRI.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
6

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 10, 2022

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

April 25, 2024

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 9, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2025

Completed
Last Updated

May 9, 2024

Status Verified

May 1, 2024

Enrollment Period

2.6 years

First QC Date

April 25, 2024

Last Update Submit

May 6, 2024

Conditions

Keywords

Gastric emptyingGastric sleeveMRIScintigraphy

Outcome Measures

Primary Outcomes (2)

  • Gastric emptying compared between patients with poor and successful weight loss

    Gastric emptying (T1/2 \[min\] and retention \[%/min\])

    2-3 years

  • Gastric emptying compared between measured with MRI and scintigraphy

    Gastric emptying (T1/2 \[min\] and retention \[%/min\])

    2-3 years

Secondary Outcomes (3)

  • Sleeve characteristics compared between patients with successful and unsuccessful (poor) weight loss

    2-3 years

  • to assess the association between gastric emptying rate and gastric sleeve characteristics in each group

    2-3 years

  • to compare subjective ratings of gastric fullness and wellbeing between patients with successful and unsuccessful weight loss

    2-3 years

Study Arms (2)

Poor weight loss group

Women aged between 20 and 55 years who underwent sleeve gastrectomy as primary procedure with TWL \< 25%

Other: MRI and scintigraphy

Successful weight loss group

Women aged between 20 and 55 years who underwent sleeve gastrectomy as primary procedure with TWL \> 35%

Other: MRI and scintigraphy

Interventions

Gastric emptying measured with MRI and scintigraphy

Poor weight loss groupSuccessful weight loss group

Eligibility Criteria

Age18 Years - 55 Years
Sexfemale(Gender-based eligibility)
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Women after sleeve gastrectomy with either good or poor weight loss

You may qualify if:

  • Women aged between 20 and 55 years who underwent sleeve gastrectomy as primary procedure with either TWL \< 25% or TWL \> 35%.
  • Patients who had a follow-up period of 2-3 years after sleeve gastrectomy

You may not qualify if:

  • Maximum BMI \>50 kg/m2
  • Patients with a disease known to affect appetite, gastric emptying or gastrointestinal motility
  • Patients who are unable to stop medications that affect gastric emptying and/or motility prior to measurements. It is depending on t1/2 for how long they need to stop medication
  • Patients who started menopause
  • Patients with gastrointestinal problems or, gastric or intestinal diseases
  • Patients with a drug or alcohol addiction
  • Patients who are unable to stop smoking for 24h
  • Patients who are pregnant or lactating
  • Patients who have an intolerance or allergy for one of the components of the test product
  • Patients who have a contra-indication to MRI scanning

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rijnstate Hospital

Arnhem, Gelderland, 6815AD, Netherlands

RECRUITING

MeSH Terms

Interventions

Magnetic Resonance Spectroscopy

Intervention Hierarchy (Ancestors)

Spectrum AnalysisChemistry Techniques, AnalyticalInvestigative Techniques

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 25, 2024

First Posted

May 9, 2024

Study Start

May 10, 2022

Primary Completion

December 31, 2024

Study Completion

May 31, 2025

Last Updated

May 9, 2024

Record last verified: 2024-05

Locations